MetaCap

Vyome (HIND) vs Lexaria Bioscience (LEXX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexaria Bioscience is the larger company by market cap ($8.5 million vs $8.4 million), about 1.0 times the size. Lexaria Bioscience converts more of its revenue into profit, with a net margin of -1686.0% versus -3209.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HIND-41.18%LEXX+16.47%
+39%-3%-45%
Oct 7, 20261 yearNov 20, 2026
HIND-42.58%LEXX+21.39%
+39%-4%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HIND versus LEXX key metrics
MetricHINDLEXX
Share price$1.20$4.03
Market cap$8.42M$8.49M
1-day change-17.24%-10.24%
YTD return-65.12%—
1-year return-75.90%—
5-year return-100.00%—
P/E ratio (TTM)0.25—
EPS (TTM)$4.77$-5.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$319.71K$705.92K
Revenue growth (YoY)+24.43%+52.05%
Net income (latest FY)$-10.26M$-11.90M
Gross margin68.43%99.61%
Operating margin-3269.35%-1683.01%
Net margin-3209.75%-1686.00%
52-week high$5.88$21.60
52-week low$1.20$2.43
Distance from 52-week high-79.59%-81.34%
Analyst consensusstrong_buynone
Avg. price target upside+635.83%+1947.15%
Average volume13.92K70.52K
Shares outstanding7.02M2.11M
Employees97
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lexaria Bioscience is more profitable, keeping -1686.0 cents of every revenue dollar as net income versus -3209.7 cents for Vyome.
  • Lexaria Bioscience grew revenue faster in its latest fiscal year (+52.05% vs +24.43%).

About Vyome

HIND stock →

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Lexaria Bioscience

LEXX stock →

Lexaria Bioscience Corp. operates as a biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

HIND vs LEXX FAQ

Which is bigger, Vyome or Lexaria Bioscience?

Lexaria Bioscience (LEXX) is larger, with a market capitalization of $8.49M compared with $8.42M for Vyome (HIND).

Are Vyome and Lexaria Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons